Repros Therapeutics - On June 8, 2008, the Compensation and Option...

Repros Therapeutics - Recent Material Event

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->


Item 5.02.		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 8, 2008, the Compensation and Option Committee of the Board of Directors of Repros Therapeutics Inc. (the “Committee”) approved a base salary increase retroactive to June 1, 2008 of 10% for the following named executive officers: Andre van As, M.D., Ph.D., the Company’s Senior Vice President, Clinical and Regulatory, and Chief Medical Officer, and Ronald Wiehle, Ph.D., the Company’s Vice President, Research and Development. As a result of this increase, effective June 1, 2008 their annual salaries are as follows:

Dr. van As $287,100

Dr. Wiehle $165,000

The Committee also approved, effective June 6, 2008, the grant of an option to purchase the Company’s common stock to each of Dr. van As and Dr. Wiehle for 30,000 shares and 20,000 shares, respectively. The options have an exercise price per share of $10.65, the closing price per share of the Company’s common stock as reported by the Nasdaq Stock Market on June 6, 2008, the last trading day prior to the date of grant, since the date of grant was not a trading day. The options vest and become exercisable at a rate of 1/12th per quarter for a period of 3 years.


Item 8.01.		Other Information

On June 9, 2008, the Company released initial findings from evaluation of gross necropsies conducted upon completion of the in-life portion of a six-month mouse study related to Proellex.

A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.


Item 9.01.		Financial Statements and Exhibits

c. Exhibits


Exhibit
Number		Description
	99.1	Press Release dated June 9, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Repros Therapeutics Inc.
Date: June 10, 2008.	By:	/s/ Louis Ploth, Jr.
		Louis Ploth, Jr.
		Vice President, Business Development and Chief Financial Officer